managing-gynecologic-screening

# Managing Gynecologic Screening

Applies ASCCP risk-based cervical cancer screening guidelines, Bethesda System cytology classification, HPV co-testing protocols, and colposcopy indications for evidence-based cervical cancer prevention.

## Why This Skill Exists

Cervical cancer is a largely preventable disease through screening and HPV vaccination. The 2019 ASCCP Risk-Based Management Consensus Guidelines replaced the prior algorithm-based approach with a risk-estimation framework where management is determined by the patient's estimated risk of CIN 3+ rather than by individual test results alone. The Bethesda System for Reporting Cervical Cytology provides the standardized terminology (ASC-US, LSIL, HSIL, AGC, etc.) that clinicians must use when documenting results.

Errors in screening management — over-screening low-risk patients, under-screening high-risk patients, or failing to refer for colposcopy when indicated — contribute to both unnecessary procedures and missed cancers. This skill ensures that every screening decision follows the ASCCP risk thresholds and is properly documented.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. **Patient age** — screening recommendations vary by age group. (Default: from demographics)
2. **HPV vaccination status** — vaccinated patients still require screening per guidelines. (Default: from immunization record)
3. **Screening history** — last Pap/HPV test date and results? Any prior abnormal results? (Default: from prior lab reports)
4. **HIV status** — HIV-positive patients have separate screening intervals. (Default: from chart)
5. **Immunosuppression status** — organ transplant, chronic steroid use, other immunosuppression? (Default: from problem list)
6. **Prior treatment history** — LEEP, cone biopsy, cryotherapy, or hysterectomy? (Default: from surgical history)
7. **Pregnancy status** — Pap screening may be performed but colposcopy management differs in pregnancy. (Default: confirm)
8. **DES exposure** — in utero DES exposure requires specialized screening. (Default: ask if age-appropriate)

### Documents to Request

- Prior Pap smear results with Bethesda classification
- HPV testing results (genotyping: HPV 16/18 vs. other high-risk types)
- Colposcopy reports and biopsy pathology
- Prior LEEP/cone operative and pathology reports
- HIV test results
- Immunization records (HPV vaccine series)

---

## Step 1: Apply Age-Based Screening Intervals

Per USPSTF/ACOG/ACS/ASCCP recommendations:

| Age Group | Screening Recommendation |
|---|---|
| < 21 years | No screening regardless of sexual history or HPV vaccination |
| 21–24 years | Cytology alone every 3 years; NO HPV co-testing |
| 25–29 years | Cytology every 3 years, OR HPV primary screening every 5 years (per ACS 2020 update) |
| 30–65 years | Cytology + HPV co-testing every 5 years (preferred), OR cytology alone every 3 years, OR HPV primary screening every 5 years |
| > 65 years | Discontinue if adequate prior screening (3 consecutive negative cytology or 2 consecutive negative co-tests in prior 10 years, most recent within 5 years) and no history of CIN 2+ in prior 25 years |
| Post-hysterectomy (with cervix removed) | Discontinue if no history of CIN 2+ and cervix fully removed |

**Special populations:**
- **HIV-positive:** Begin screening at age 21, cytology annually; co-testing every 3 years if age ≥ 30 with normal results × 3
- **Immunosuppressed (non-HIV):** Screen per HIV guidelines
- **In utero DES exposure:** Annual cytology starting at age of diagnosis

---

## Step 2: Interpret Results Using the Bethesda System

### Cytology Categories (Bethesda 2014)

| Bethesda Category | Meaning | Clinical Significance |
|---|---|---|
| NILM | Negative for intraepithelial lesion or malignancy | Normal result |
| ASC-US | Atypical squamous cells of undetermined significance | Mildly abnormal; reflex HPV testing indicated |
| ASC-H | Atypical squamous cells, cannot exclude HSIL | Higher concern; colposcopy recommended |
| LSIL | Low-grade squamous intraepithelial lesion | Corresponds to HPV effect / CIN 1 |
| HSIL | High-grade squamous intraepithelial lesion | Corresponds to CIN 2/3; colposcopy required |
| AGC | Atypical glandular cells | Requires colposcopy + endocervical curettage ± endometrial biopsy |
| AIS | Adenocarcinoma in situ | Requires colposcopy, ECC, and excisional procedure |
| SCC | Squamous cell carcinoma | Invasive cancer — urgent gynecologic oncology referral |

### HPV Results
- **HPV negative** — low risk, return to routine screening
- **HPV positive (other high-risk, non-16/18)** — risk depends on cytology
- **HPV 16 positive** — highest risk; colposcopy regardless of cytology
- **HPV 18 positive** — high risk; colposcopy regardless of cytology

---

## Step 3: Apply the 2019 ASCCP Risk-Based Framework

Management is based on the **estimated CIN 3+ risk** using current and prior test results:

| Estimated CIN 3+ Risk | Recommended Action |
|---|---|
| < 0.15% | Return to routine 5-year screening |
| 0.15–0.54% | Return in 3 years for repeat testing |
| 0.55–3.9% | Return in 1 year for repeat testing |
| 4.0–24% | Colposcopy recommended |
| 25–59% | Colposcopy with biopsy; treatment acceptable |
| 60–100% | Excisional treatment recommended (LEEP or cold knife cone) |

**Key clinical action thresholds:**
- **ASC-US / HPV negative:** Return in 3 years (low risk)
- **ASC-US / HPV positive (non-16/18):** Return in 1 year
- **ASC-US / HPV 16 or 18 positive:** Colposcopy
- **LSIL / HPV negative (ages 25+):** Return in 1 year
- **LSIL / HPV positive:** Colposcopy
- **HSIL (any HPV result):** Colposcopy; expedited treatment (LEEP) acceptable if not pregnant
- **AGC:** Colposcopy + ECC + endometrial biopsy (if age ≥ 35 or risk factors for endometrial cancer)

---

## Step 4: Colposcopy Documentation Requirements

When colposcopy is performed, document:

1. **Indication** — cytology result, HPV status, ASCCP risk estimate
2. **Adequacy** — visualization of entire squamocolumnar junction (SCJ) — adequate vs. inadequate
3. **Findings** — acetowhite epithelium, punctation, mosaicism, atypical vessels, lesion size and location (clock positions)
4. **Biopsy location(s)** — number and clock positions of biopsies taken
5. **Endocervical curettage (ECC)** — performed or not, indication
6. **Impression** — low-grade vs. high-grade colposcopic impression
7. **Pathology results** — CIN 1, CIN 2, CIN 3, AIS, invasive carcinoma
8. **Management plan** — surveillance vs. excision based on pathology and ASCCP guidelines

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. **Is the screening interval appropriate** for the patient's age and risk profile?
2. **Are all test results documented** with Bethesda terminology for cytology and specific HPV genotype data?
3. **Does the management plan match** the ASCCP risk-based recommendation for the test result combination?
4. **Is the colposcopy referral documented** when indicated, or is the surveillance plan clearly stated?
5. **Are special populations flagged** — HIV, immunosuppressed, post-treatment, DES exposure?

---

## Quality Audit

- [ ] Patient age documented and screening interval matches age-based recommendation
- [ ] Cytology result documented using Bethesda System terminology
- [ ] HPV result documented with genotype specificity (16, 18, other high-risk, negative)
- [ ] ASCCP risk estimate or risk category is stated
- [ ] Colposcopy referral documented when CIN 3+ risk ≥ 4%
- [ ] Colposcopy adequacy (SCJ visualization) documented when performed
- [ ] Biopsy results documented with CIN grade
- [ ] ECC performed and results documented for AGC or unsatisfactory colposcopy
- [ ] Prior abnormal results are referenced when estimating current risk
- [ ] Treatment plan (surveillance vs. excision) is stated with next follow-up date
- [ ] HIV and immunosuppression screening protocols applied when applicable
- [ ] Post-treatment surveillance documented (at 6 months, 12 months, then annually × 3 years, then every 3 years × 25 years)
- [ ] HPV vaccination status documented and vaccine offered if eligible (up to age 45)

---

## Guidelines

1. **Use Bethesda terminology exclusively** — never write "Class II" or "mild dysplasia" in place of the standardized Bethesda terms.
2. **Always pair cytology with HPV result** — isolated cytology interpretation without HPV context leads to incorrect risk estimation.
3. **Do not over-screen** — annual Pap smears are not recommended for average-risk patients over age 30 with negative co-testing; the interval is 5 years.
4. **Age 21–24 is a special group** — LSIL and ASC-US in this age group are managed conservatively due to high regression rates. Do NOT perform HPV co-testing.
5. **AGC triggers a broader workup** — always include ECC and consider endometrial biopsy, especially in patients ≥ 35 or with abnormal bleeding.
6. **Post-treatment surveillance is 25 years** — patients with treated CIN 2+ remain at elevated risk for at least 25 years and must not return to standard population-based screening intervals.
7. **Document the "adequate negative prior" determination** when discontinuing screening at age 65 — list the specific tests and dates that meet exit criteria.